Treatment of Tinea Corporis with Terbinafine

Introduction to Terbinafine Therapy

• The American Academy of Pediatrics recommends switching to terbinafine as an appropriate and evidence-based alternative when clotrimazole fails to treat tinea corporis, with both topical and oral formulations showing superior efficacy to clotrimazole in clinical trials 1

Oral Terbinafine Dosage

• For patients over 40 kg, the recommended oral terbinafine dose is 250 mg once daily for 2-4 weeks 1, 2

Alternative Therapies

• Oral itraconazole 100 mg once daily for 15 days achieves 87% mycological cure rates in adolescents and adults with tinea corporis 2
• Ciclopirox olamine 0.77% cream/gel applied twice daily for 4 weeks shows superior efficacy to clotrimazole 1

Contraindications and Safety Considerations

• The British Association of Dermatologists notes that oral terbinafine is contraindicated in patients with active or chronic liver disease, lupus erythematosus, porphyria, or known hypersensitivity to oral terbinafine 3

Treatment Endpoints and Pitfalls

• The British Association of Dermatologists recommends that the endpoint of treatment should be mycological cure (negative microscopy and culture), not just clinical improvement, as clinical appearance may improve while infection persists 3
• If clinical improvement occurs but mycology remains positive, continue therapy for an additional 2-4 weeks 3

Prevention of Recurrence

• To prevent recurrence, avoid skin-to-skin contact with infected individuals, do not share towels or personal items, and limit exposure to swimming pools associated with outbreaks 1

Drug Interactions

• Terbinafine interacts with multiple medications, including cyclosporine, fluconazole, and caffeine, and requires monitoring or adjustment when co-administered 2, 3

Alternative Topical Antifungals for Tinea Corporis

First-Line Alternative Topical Antifungals

• Ciclopirox olamine 0.77% cream/gel is applied twice daily for 4 weeks, showing effectiveness in eradicating dermatophyte infections with superior clinical and mycological cure rates (approximately 60% at end of treatment and 85% two weeks after treatment), as recommended by the American Academy of Pediatrics 4

Special Considerations and Precautions

• For extensive tinea corporis or cases with poor response to topical therapy, oral antifungal agents may be considered, according to the American Academy of Pediatrics 4
• Oral itraconazole (100 mg daily for 15 days) has shown 87% mycological cure rate in adolescents and adults with tinea corporis, as reported by the American Academy of Pediatrics 4

Prevention Measures

• Avoid skin-to-skin contact with people known to have lesions, as advised by the American Academy of Pediatrics 4
• Do not share towels and other personal items that could serve as fomites, as recommended by the American Academy of Pediatrics 4
• Limit exposure to swimming pools that have recently been associated with known outbreaks, according to the American Academy of Pediatrics 4

Contraindications and Safety Considerations for Oral Terbinafine

Contraindications

Adverse Effects

Oral Terbinafine: Contraindications and Safety Monitoring

Contraindications

• Oral terbinafine should not be prescribed to individuals with active or chronic liver disease, as these conditions increase the risk of hepatotoxicity. 6

Baseline Laboratory Assessment

• Prior to starting oral terbinafine, obtain baseline liver‑function tests and a complete blood count in patients who have a history of heavy alcohol consumption, prior hepatitis, or any hematologic disorder, to detect pre‑existing abnormalities that could be exacerbated by therapy. 6

Adverse‑Effect Counseling

• Inform patients that oral terbinafine carries a rare risk of permanent taste disturbance; counseling should be provided before therapy initiation. 6